KYNAM CAPITAL MANAGEMENT, LP Holdings

KYNAM CAPITAL MANAGEMENT, LP is an investment fund managing more than 474.57M US dollars. The largest holdings include Natera, Syndax Pharmaceuticals and Celldex Therapeutics. In Q3 2022 the fund bought assets of total value of 182.71M US dollars and sold assets of total value of 97.32M US dollars.

$474.56M

portfolio value

+37.28%

quarter

KYNAM CAPITAL MANAGEMENT, LP portfolio changes

Portfolio changes (number of shares)
Period	Buy	Sel
Q1 2022	140557000	16651000
Q2 2022	101424000	21441000
Q3 2022	182705000	97324000

KYNAM CAPITAL MANAGEMENT, LP 13F holdings

Stock	Position type	Portfolio share	Portfolio value	Avg. open price	Current price	P/L	Last change
Diagnostics & Research Natera, Inc. Portfolio share: 18.64% Portfolio value: 88.44M Avg. open price: $36.8 Current price: $40.39 P/L: +9.76% Bought +62.90% shares Q3 2022	share	18.64%	88.44M	$36.8	$40.39	+9.76%	Bought +62.90% shares Q3 2022
Biotechnology Syndax Pharmaceuticals, Inc. Portfolio share: 11.51% Portfolio value: 54.61M Avg. open price: $20.14 Current price: $25.44 P/L: +26.31% Sold -9.53% shares Q3 2022	share	11.51%	54.61M	$20.14	$25.44	+26.31%	Sold -9.53% shares Q3 2022
Biotechnology Celldex Therapeutics, Inc. Portfolio share: 9.48% Portfolio value: 44.98M Avg. open price: $33.5 Current price: $36.66 P/L: +9.45% Bought +41.32% shares Q3 2022	share	9.48%	44.98M	$33.5	$36.66	+9.45%	Bought +41.32% shares Q3 2022
Biotechnology Vera Therapeutics, Inc. Portfolio share: 6.90% Portfolio value: 32.73M Avg. open price: $23.74 Current price: $16.19 P/L: -31.80% Bought +0.88% shares Q3 2022	share	6.90%	32.73M	$23.74	$16.19	-31.80%	Bought +0.88% shares Q3 2022
Biotechnology United Therapeutics Corporation Portfolio share: 6.66% Portfolio value: 31.61M Avg. open price: N/A Current price: $273.72 P/L: N/A N/A Q3 2022	share	6.66%	31.61M	N/A	$273.72	N/A	N/A Q3 2022
Drug Manufacturers—General Sanofi Portfolio share: 4.81% Portfolio value: 22.81M Avg. open price: N/A Current price: $44.93 P/L: N/A N/A Q3 2022	share	4.81%	22.81M	N/A	$44.93	N/A	N/A Q3 2022
Biotechnology Viridian Therapeutics, Inc. Portfolio share: 4.32% Portfolio value: 20.51M Avg. open price: $15.27 Current price: $26.84 P/L: +75.72% Bought +69.45% shares Q3 2022	share	4.32%	20.51M	$15.27	$26.84	+75.72%	Bought +69.45% shares Q3 2022
Drug Manufacturers—General Biogen Inc. Portfolio share: 4.22% Portfolio value: 20.02M Avg. open price: $210.6 Current price: $292.75 P/L: +39.01% Sold -5.00% shares Q3 2022	share	4.22%	20.02M	$210.6	$292.75	+39.01%	Sold -5.00% shares Q3 2022
Biotechnology Vaxcyte, Inc. Portfolio share: 3.53% Portfolio value: 16.76M Avg. open price: $25.08 Current price: $44.33 P/L: +76.72% Sold -3.47% shares Q3 2022	share	3.53%	16.76M	$25.08	$44.33	+76.72%	Sold -3.47% shares Q3 2022
Diagnostics & Research Burning Rock Biotech Limited Portfolio share: 3.38% Portfolio value: 16.02M Avg. open price: $6.9 Current price: $2.41 P/L: -65.08% Bought +55.90% shares Q3 2022	share	3.38%	16.02M	$6.9	$2.41	-65.08%	Bought +55.90% shares Q3 2022
Drug Manufacturers—General GSK plc Portfolio share: 3.10% Portfolio value: 14.71M Avg. open price: N/A Current price: $35.16 P/L: N/A N/A Q3 2022	share	3.10%	14.71M	N/A	$35.16	N/A	N/A Q3 2022
Biotechnology Cogent Biosciences, Inc. Portfolio share: 3.10% Portfolio value: 14.69M Avg. open price: N/A Current price: $12.5 P/L: N/A Sold -1.48% shares Q3 2022	share	3.10%	14.69M	N/A	$12.5	N/A	Sold -1.48% shares Q3 2022
Biotechnology Concert Pharmaceuticals, Inc. Portfolio share: 2.36% Portfolio value: 11.20M Avg. open price: $4.21 Current price: $4.76 P/L: +13.06% Bought +67.30% shares Q3 2022	share	2.36%	11.20M	$4.21	$4.76	+13.06%	Bought +67.30% shares Q3 2022
Biotechnology Travere Therapeutics, Inc. Portfolio share: 2.16% Portfolio value: 10.26M Avg. open price: $28.74 Current price: $20.01 P/L: -30.38% Sold -66.26% shares Q3 2022	share	2.16%	10.26M	$28.74	$20.01	-30.38%	Sold -66.26% shares Q3 2022
Biotechnology Liquidia Corporation Portfolio share: 1.94% Portfolio value: 9.20M Avg. open price: $6.17 Current price: $5.18 P/L: -15.98% Bought +12.77% shares Q3 2022	share	1.94%	9.20M	$6.17	$5.18	-15.98%	Bought +12.77% shares Q3 2022
Biotechnology Global Blood Therapeutics, Inc. Portfolio share: 1.88% Portfolio value: 8.93M Avg. open price: $33.27 Current price: $68.49 P/L: +105.87% Sold -94.04% shares Q3 2022	share	1.88%	8.93M	$33.27	$68.49	+105.87%	Sold -94.04% shares Q3 2022
Biotechnology AMARIN CORP PLC Portfolio share: 1.54% Portfolio value: 7.32M Avg. open price: $2.21 Current price: $1.18 P/L: -46.81% Bought +67.59% shares Q3 2022	share	1.54%	7.32M	$2.21	$1.18	-46.81%	Bought +67.59% shares Q3 2022
Biotechnology Amicus Therapeutics, Inc. Portfolio share: 1.49% Portfolio value: 7.06M Avg. open price: $9.47 Current price: $12.37 P/L: +30.62% Sold -24.79% shares Q3 2022	share	1.49%	7.06M	$9.47	$12.37	+30.62%	Sold -24.79% shares Q3 2022
Biotechnology BioCryst Pharmaceuticals, Inc. Portfolio share: 1.16% Portfolio value: 5.48M Avg. open price: N/A Current price: $11.58 P/L: N/A Sold -53.54% shares Q3 2022	share	1.16%	5.48M	N/A	$11.58	N/A	Sold -53.54% shares Q3 2022
Biotechnology Wave Life Sciences Ltd. Portfolio share: 1.06% Portfolio value: 5.04M Avg. open price: $3.28 Current price: $4.25 P/L: +29.57% Sold -17.64% shares Q3 2022	share	1.06%	5.04M	$3.28	$4.25	+29.57%	Sold -17.64% shares Q3 2022
Biotechnology Seres Therapeutics, Inc. Portfolio share: 1.05% Portfolio value: 4.96M Avg. open price: $3.43 Current price: $6.53 P/L: +90.38% Bought +198.79% shares Q3 2022	share	1.05%	4.96M	$3.43	$6.53	+90.38%	Bought +198.79% shares Q3 2022
Biotechnology Akouos, Inc. Portfolio share: 1.02% Portfolio value: 4.85M Avg. open price: $6.4 Current price: $13.29 P/L: +107.82% Bought +87.19% shares Q3 2022	share	1.02%	4.85M	$6.4	$13.29	+107.82%	Bought +87.19% shares Q3 2022
Biotechnology Gossamer Bio, Inc. Portfolio share: 0.98% Portfolio value: 4.62M Avg. open price: $10.27 Current price: $9.29 P/L: -9.55% Sold -83.56% shares Q3 2022	share	0.98%	4.62M	$10.27	$9.29	-9.55%	Sold -83.56% shares Q3 2022
Biotechnology Protagonist Therapeutics, Inc. Portfolio share: 0.92% Portfolio value: 4.37M Avg. open price: N/A Current price: $7.8 P/L: N/A N/A Q3 2022	share	0.92%	4.37M	N/A	$7.8	N/A	N/A Q3 2022
Biotechnology Olema Pharmaceuticals, Inc. Portfolio share: 0.81% Portfolio value: 3.86M Avg. open price: $4.07 Current price: $2.79 P/L: -31.45% Bought +461.59% shares Q3 2022	share	0.81%	3.86M	$4.07	$2.79	-31.45%	Bought +461.59% shares Q3 2022
Biotechnology Centessa Pharmaceuticals plc Portfolio share: 0.62% Portfolio value: 2.94M Avg. open price: $11.27 Current price: $3.93 P/L: -65.14% Sold -3.47% shares Q3 2022	share	0.62%	2.94M	$11.27	$3.93	-65.14%	Sold -3.47% shares Q3 2022
Biotechnology Affimed N.V. Portfolio share: 0.29% Portfolio value: 1.39M Avg. open price: $4.37 Current price: $2.12 P/L: -51.60% Sold -3.47% shares Q3 2022	share	0.29%	1.39M	$4.37	$2.12	-51.60%	Sold -3.47% shares Q3 2022
Biotechnology Puma Biotechnology, Inc. Portfolio share: 0.28% Portfolio value: 1.32M Avg. open price: N/A Current price: $4.31 P/L: N/A Sold -3.47% shares Q3 2022	share	0.28%	1.32M	N/A	$4.31	N/A	Sold -3.47% shares Q3 2022
Biotechnology Xenon Pharmaceuticals Inc. Portfolio share: 0.22% Portfolio value: 1.03M Avg. open price: N/A Current price: $38.83 P/L: N/A Sold -83.55% shares Q3 2022	share	0.22%	1.03M	N/A	$38.83	N/A	Sold -83.55% shares Q3 2022
Biotechnology Connect Biopharma Holdings Limited Portfolio share: 0.20% Portfolio value: 954K Avg. open price: $3.02 Current price: $0.71 P/L: -76.42% Bought +224.75% shares Q2 2022	share	0.20%	954K	$3.02	$0.71	-76.42%	Bought +224.75% shares Q2 2022
Biotechnology Relmada Therapeutics, Inc. Portfolio share: 0.17% Portfolio value: 803K Avg. open price: N/A Current price: $4.45 P/L: N/A N/A Q3 2022	put	0.17%	803K	N/A	$4.45	N/A	N/A Q3 2022
Biotechnology Cabaletta Bio, Inc. Portfolio share: 0.07% Portfolio value: 343K Avg. open price: N/A Current price: $4.97 P/L: N/A Sold -3.47% shares Q3 2022	share	0.07%	343K	N/A	$4.97	N/A	Sold -3.47% shares Q3 2022
Biotechnology Tricida, Inc. Portfolio share: 0.07% Portfolio value: 338K Avg. open price: N/A Current price: $0.23 P/L: N/A N/A Q3 2022	call	0.07%	338K	N/A	$0.23	N/A	N/A Q3 2022
Biotechnology Tricida, Inc. Portfolio share: 0.03% Portfolio value: 122K Avg. open price: N/A Current price: $0.23 P/L: N/A N/A Q3 2022	put	0.03%	122K	N/A	$0.23	N/A	N/A Q3 2022
Drug Manufacturers—Specialty & Generic Neoleukin Therapeutics, Inc. Portfolio share: 0.02% Portfolio value: 77K Avg. open price: N/A Current price: $0.43 P/L: N/A Sold -3.47% shares Q3 2022	share	0.02%	77K	N/A	$0.43	N/A	Sold -3.47% shares Q3 2022
Biotechnology Catalyst Biosciences, Inc. Portfolio share: 0.01% Portfolio value: 45K Avg. open price: N/A Current price: $0.55 P/L: N/A Sold -3.47% shares Q3 2022	share	0.01%	45K	N/A	$0.55	N/A	Sold -3.47% shares Q3 2022
Biotechnology Liquidia Corporation Portfolio share: 0.00% Portfolio value: 13K Avg. open price: $6.17 Current price: $5.18 P/L: -15.98% N/A Q3 2022	call	0.00%	13K	$6.17	$5.18	-15.98%	N/A Q3 2022
Biotechnology Fate Therapeutics, Inc. Portfolio share: 0.00% Portfolio value: 0 Avg. open price: N/A Current price: $20.4 P/L: N/A Sold -100.00% shares Q3 2022	share	0.00%	0	N/A	$20.4	N/A	Sold -100.00% shares Q3 2022
Biotechnology Celldex Therapeutics, Inc. Portfolio share: 0.00% Portfolio value: 0 Avg. open price: $33.5 Current price: $36.66 P/L: +9.45% Sold -100.00% shares Q3 2022	call	0.00%	0	$33.5	$36.66	+9.45%	Sold -100.00% shares Q3 2022
Biotechnology Alnylam Pharmaceuticals, Inc. Portfolio share: 0.00% Portfolio value: 0 Avg. open price: N/A Current price: $226.4 P/L: N/A Sold -100.00% shares Q3 2022	put	0.00%	0	N/A	$226.4	N/A	Sold -100.00% shares Q3 2022
Biotechnology Karuna Therapeutics, Inc. Portfolio share: 0.00% Portfolio value: 0 Avg. open price: N/A Current price: $226.95 P/L: N/A Sold -100.00% shares Q3 2022	put	0.00%	0	N/A	$226.95	N/A	Sold -100.00% shares Q3 2022
Biotechnology Merus N.V. Portfolio share: 0.00% Portfolio value: 0 Avg. open price: N/A Current price: $14.2 P/L: N/A Sold -100.00% shares Q3 2022	share	0.00%	0	N/A	$14.2	N/A	Sold -100.00% shares Q3 2022

Showing TOP 42 KYNAM CAPITAL MANAGEMENT, LP's 13F holdings.

Frequently Asked Questions (FAQ)

What is the biggest position of KYNAM CAPITAL MANAGEMENT, LP?

The biggest position of the KYNAM CAPITAL MANAGEMENT, LP is Natera, Inc. (NTRA) with 18.64% portfolio share worth of 88.45M US dollars.

Top 5 KYNAM CAPITAL MANAGEMENT, LP's holdings represent 53.18% of the portfolio:

Natera, Inc. (NTRA) – 18.64%
Syndax Pharmaceuticals, Inc. (SNDX) – 11.51%
Celldex Therapeutics, Inc. (CLDX) – 9.48%
Vera Therapeutics, Inc. (VERA) – 6.9%
United Therapeutics Corporation (UTHR) – 6.66%

Who is the portfolio manager of KYNAM CAPITAL MANAGEMENT, LP?

The portfolio manager of the KYNAM CAPITAL MANAGEMENT, LP is .

What is the total asset value of the KYNAM CAPITAL MANAGEMENT, LP portfolio?

KYNAM CAPITAL MANAGEMENT, LP total asset value (portfolio value) is 474.57M US dollars.

Who is ?

is the portfolio manager of the KYNAM CAPITAL MANAGEMENT, LP.

What is (KYNAM CAPITAL MANAGEMENT, LP) fund performance?

KYNAM CAPITAL MANAGEMENT, LP's quarterly performance is +37.28%, annualy 0.00%.

What is the KYNAM CAPITAL MANAGEMENT, LP CIK?

KYNAM CAPITAL MANAGEMENT, LP's Central Index Key is 0001907884 .